Ventas (VTR)

NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-10-15

$85.86+1.18%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Ventas’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.4%

+10% or more+5%0%−5%−10% or less

0.94 → 0.95 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS guidance raised to $0.59 per share for 2026	Earnings guidance was raised to $0.59 per share for 2026.	Intact	EPS guidance falls below $0.56 for FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Liquidity at least $5.5 billion	Liquidity improved to $5.5 billion, supporting growth.	Intact	liquidity falls below $5 billion	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Net Debt-to-Further Adjusted EBITDA improved from 5.2x in 2025-Q4 to 5.0x in 2026-Q1 and further to 4.7x in 2026-Q2, showing deleveraging. Liquidity remained strong at $4.9 billion in 2026-Q2, slightly down from $5.5 billion in 2026-Q1. Management is delivering improved financial flexibility and maintaining liquidity to support growth. Delivery assessment Oct 15, 2026
Increase senior housing investments to $3 billion in 2026	Ventas grows senior housing investments to $3 billion in 2026.	Intact	total senior housing investments fall below $2.5 billion in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Investment volume guidance increased from $2.5 billion in 2025-Q4 to $3 billion in 2026-Q1 and further to $4.5 billion in 2026-Q2, with over $3 billion of senior housing investments completed year to date by 2026-Q2. Management is delivering on expanding senior housing investments with a clear upward trajectory. Delivery assessment Oct 15, 2026
SHOP Same-Store Cash NOI growth > 15% YoY	SHOP Same-Store Cash NOI rose over 15% year-over-year in Q1.	Under Pressure	SHOP Same-Store Cash NOI growth falls below 10% YoY in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.95

Unavailable → $0.95 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	$1.02	Unavailable	5 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	$1.02	Unavailable	5 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	$1.02	Unavailable	5 / 3
2026-08-02	$1.01	Unavailable	5 / 3
2026-08-03	$1.01	Unavailable	5 / 3
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	$1.01	Unavailable	5 / 3
2026-08-06	$1.01	Unavailable	5 / 3
2026-08-08	$1.01	Unavailable	5 / 3
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-12	$1.01	Unavailable	5 / 3
2026-08-13	$1.01	Unavailable	5 / 3
2026-08-14	$1.01	Unavailable	5 / 3
2026-08-15	$1.01	Unavailable	5 / 3
2026-08-16	$1.01	Unavailable	5 / 3
2026-08-17	$1.01	Unavailable	5 / 3
2026-08-18	$1.01	Unavailable	5 / 4
2026-08-19	$1.01	Unavailable	5 / 4
2026-08-20	$0.98	Unavailable	6 / 4
2026-08-21	$0.98	Unavailable	6 / 4
2026-08-22	$0.97	Unavailable	6 / 4
2026-08-23	$0.97	Unavailable	6 / 4
2026-08-24	$0.97	Unavailable	6 / 4
2026-08-25	$0.97	Unavailable	6 / 4
2026-08-26	$0.95	Unavailable	6 / 4
2026-08-27	$0.95	Unavailable	6 / 4
2026-08-28	$0.95	Unavailable	6 / 4
2026-08-29	$0.95	$7,630,342,106	6 / 5
2026-08-30	$0.95	$7,630,342,106	6 / 5
2026-08-31	$0.95	$7,630,342,106	6 / 5
2026-09-01	$0.95	$7,630,342,106	6 / 5
2026-09-02	$0.95	$7,630,342,106	6 / 5
2026-09-03	$0.94	$7,658,095,386	6 / 5
2026-09-04	$0.94	$7,658,116,990	6 / 5
2026-09-05	$0.94	$7,658,116,990	6 / 5
2026-09-06	$0.94	$7,658,116,990	6 / 5
2026-09-07	$0.94	$7,658,116,990	6 / 5
2026-09-08	$0.94	$7,658,116,990	6 / 5
2026-09-09	$0.94	$7,658,116,990	6 / 5
2026-09-10	$0.94	$7,658,116,990	6 / 5
2026-09-11	$0.94	$7,658,116,990	6 / 5
2026-09-12	$0.94	$7,658,116,990	6 / 5
2026-09-13	$0.94	$7,658,116,990	6 / 5
2026-09-14	$0.94	$7,658,116,990	6 / 5
2026-09-15	$0.94	$7,658,116,990	6 / 5
2026-09-16	$0.94	$7,658,116,990	6 / 5
2026-09-17	$0.94	$7,658,116,990	6 / 5
2026-09-18	$0.94	$7,658,116,990	6 / 5
2026-09-19	$0.94	$7,658,116,990	6 / 5
2026-09-20	$0.94	Unavailable	6 / 4
2026-09-21	$0.94	Unavailable	6 / 4
2026-09-22	$0.94	Unavailable	6 / 4
2026-09-23	$0.94	Unavailable	6 / 4
2026-09-24	$0.94	Unavailable	6 / 4
2026-09-25	$0.94	Unavailable	6 / 4
2026-09-26	$0.94	Unavailable	6 / 4
2026-09-27	$0.94	Unavailable	6 / 4
2026-09-28	$0.94	Unavailable	6 / 4
2026-09-29	$0.94	Unavailable	6 / 4
2026-09-30	$0.94	Unavailable	6 / 4
2026-10-01	$0.94	Unavailable	6 / 4
2026-10-02	$0.94	Unavailable	6 / 4
2026-10-03	$0.94	Unavailable	6 / 4
2026-10-04	$0.94	Unavailable	6 / 4
2026-10-05	$0.94	Unavailable	6 / 4
2026-10-06	$0.94	Unavailable	6 / 4
2026-10-07	$0.94	Unavailable	6 / 4
2026-10-08	$0.94	Unavailable	6 / 4
2026-10-09	$0.94	Unavailable	6 / 4
2026-10-10	$0.94	Unavailable	6 / 4
2026-10-11	$0.95	Unavailable	6 / 4
2026-10-12	$0.95	Unavailable	6 / 4
2026-10-13	$0.95	Unavailable	6 / 3
2026-10-14	$0.95	Unavailable	6 / 3
2026-10-15	$0.95	Unavailable	6 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	17	4	0
2026-06-01	18	4	0
2026-07-01	18	5	1
2026-08-01	18	5	1
2026-09-01	18	5	0
2026-10-01	19	5	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 16–Oct 15 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 13 · prior Aug 31

$102.00 → $91.00-10.8%

Evercore ISISep 21 · prior Apr 29

$95.00 → $100.00+5.3%

$0$56.10$112.20

1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS guidance raised to $0.59 per share for 2026Direct metric needs a verified mapping
Liquidity at least $5.5 billionDirect metric needs a verified mapping
Increase senior housing investments to $3 billion in 2026Direct metric needs a verified mapping
SHOP Same-Store Cash NOI growth > 15% YoYPublished status: Under Pressure

Next proof point

Oct 27, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.7%Typical daily move · historical

Downside history

-20.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ventas outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on senior housing. The current thesis state is cautious due to recent weak financial performance, despite management's commitment to growth in this sector.

What's priced into Ventas

The valuation is considered expensive compared to peers, with a significant expectations gap. The market seems to be pricing in a level of performance that may not fully reflect the recent challenges faced by VTR.

What the fundamentals likely do

Management is on track with key priorities, including expanding senior housing investments and driving cash flow growth. However, recent financial performance has been weak, which could impact future results.

What Ventas hinges on

The thesis hinges on several factors, including the potential for the Federal Reserve to cut rates and the performance of sector peers like WELL, OHI, and DOC. A reversal in guidance could significantly impact credibility and investor sentiment.